Sanofi and Glaxo Are Back With a Covid-19 Vaccine

Sanofi and Glaxo Are Back With a Covid-19 Vaccine
·4 min read

Last summer, before the startling trial results that showed that vaccines from (PFE)and (MRNA)offered extraordinary levels of protection against Covid-19, there was another vaccine that was expected to be key in fighting the pandemic. The same day that the FDA authorized (PFE) (ticker: PFE) Covid-19 vaccine, however, (SAN) (SNY) and Glaxo (GSK) announced a major delay in the development of their vaccine, saying an early trial suggested that it wasn’t effective enough in older adults. In a press release issued early Monday morning in Paris, the two companies said that a 722-subject Phase 2 study of an updated version of their vaccine elicited what it called “strong” levels of neutralizing antibodies after two doses across all age groups.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting